Page 192 - Haematologica - Vol. 105 n. 6 - June 2020

Plasma Cell Disorders
Ferrata Storti Foundation
Haematologica 2020 Volume 105(1):1650-1659
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
Lene Kongsgaard Nielsen,1* Claudia Stege,2* Birgit Lissenberg-Witte,3 Bronno van der Holt,4 Ulf-Henrik Mellqvist,5 Morten Salomo,6 Gerard Bos,7 Mark-David Levin,8 Heleen Visser-Wisselaar,4 Markus Hansson,9 Annette van der Velden,10 Wendy Deenik,11 Juleon Coenen,12 Maja Hinge,13 Saskia Klein,14 Bea Tanis,15 Damian Szatkowski,16 Rolf Brouwer,17 Matthijs Westerman,18 Rineke Leys,19 Harm Sinnige,20 Einar Haukås,21 Klaas van der Hem,22 Marc Durian,23 Peter Gimsing,24 Niels van de Donk,2 Pieter Sonneveld,25 Anders Waage,26 Niels Abildgaard1 and Sonja Zweegman2
1Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark; 2Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands; 3Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands; 4HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 5Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gotheborg, Sweden; 6Department of Haematology, Rigshospitalet, Copenhagen, Denmark; 7Department of Haematology, Maastricht University Medical Center, Maastricht, the Netherlands; 8Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands; 9Department of Haematology and Wallenberg Center for Molecular Medicine, Skåne University Hospital, Lund University, Lund, Sweden; 10Department of Internal Medicine, Martini Ziekenhuis, Groningen, the Netherlands; 11Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, the Netherlands; 12Department of Internal Medicine, Isala, Zwolle, the Netherlands; 13Department of Internal Medicine, Division of Hematology, Vejle Hospital, Vejle, Denmark; 14Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, the Netherlands; 15Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands; 16Department of Oncology, Haematology and Palliative Care, Førde Central Hospital, Førde, Norway; 17Department of Internal Medicine, Reinier de Graaf Ziekenhuis, Delft, the Netherlands; 18Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands; 19Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, the Netherlands; 20Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands; 21Department of Haematology, Stavanger University Hospital, Stavanger, Norway, 22Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, the Netherlands; 23Department of Internal Medicine, Tweesteden Ziekenhuis, Tilburg, the Netherlands; 24Department of Haematology, Rigshospitalet, Copenhagen, Denmark; 25Department of Haematology, Erasmus Medical Center Cancer Center, Rotterdam, the Netherlands and 26Department of Haematology, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway
*LKN and CS contributed equally as co-first authors.
ABSTRACT
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were com- pleted at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal impor- tant differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in
Correspondence:
LENE KONGSGAARD NIELSEN
lene.kongsgaard.nielsen@rsyd.dk
Received: April 19, 2019.
Accepted: September 11, 2019. Pre-published: September 12, 2019.
doi:10.3324/haematol.2019.222299
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/105/6/1650
©2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
1650
haematologica | 2020; 105(6)
ARTICLE